Interventional Cardiology Devices – Market Insights – Europe

The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the adoption of innovative devices and technologies. Favorable clinical evidence, particularly for coronary IVL, will continue to propel the market forward. Additionally, the adoption of novel products and diagnostic methods is expected to expand the eligible patient population and support continued market growth in the coming years.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in Europe from 2019 through 2035.

The increasing prevalence of complex PCI cases will drive demand for innovative devices and result in a higher proportion of complex PCIs.

Which factors are contributing to the increasing prevalence of complex CAD cases?

What factors are influencing complex PCI procedure volume growth in the European IC device market?

Despite the increasing prevalence of complex PCIs, what factors are limiting the uptake of innovative devices in the European IC device market?

There is a growing competition in the European coronary lithotripsy device market.

What factors are driving growth in the treatment of calcified coronary artery disease using coronary lithotripsy in the European IC market?

What are the future prospects of the companies operating in the market?

Which companies are expected to launch their products in the European coronary lithotripsy device market?

Which new competitors are anticipated to enter the market?

Growing adoption of CCTA and FFR_angio is reshaping diagnostic decision making in Europe, supporting more targeted patient selection for invasive evaluation.

How is increasing adoption of CCTA and FFR_^angio influencing diagnostic pathways and downstream invasive procedure volumes in the European IC device market?

To what extent are CCTA and FFR_angio contributing to changes in PCI case selection and increasing the proportion of complex PCI procedures in Europe?

Which European countries are leading adoption of CCTA and FFR_angio, and what is the impact on invasive diagnostic and PCI volumes?